Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 624 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition

Poudel Resham Raj

Year : 2013| Volume: 17| Issue : 4 | Page no: 588-593

   This article has been cited by
 
1 Distribution of glucose transporters in renal diseases
Leszek Szablewski
Journal of Biomedical Science. 2017; 24(1)
[Pubmed]  [Google Scholar] [DOI]
2 The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
Oren Steen,Ronald M. Goldenberg
Canadian Journal of Diabetes. 2017; 41(5): 517
[Pubmed]  [Google Scholar] [DOI]
3 The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
Oren Steen,Ronald M. Goldenberg
Canadian Journal of Diabetes. 2017;
[Pubmed]  [Google Scholar] [DOI]
4 SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
Piangkwan Sa-nguanmoo,Pongpan Tanajak,Sasiwan Kerdphoo,Thidarat Jaiwongkam,Wasana Pratchayasakul,Nipon Chattipakorn,Siriporn C. Chattipakorn
Toxicology and Applied Pharmacology. 2017; 333: 43
[Pubmed]  [Google Scholar] [DOI]
5 Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Tushar Madaan,Mohd. Akhtar,Abul Kalam Najmi
European Journal of Pharmaceutical Sciences. 2016;
[Pubmed]  [Google Scholar] [DOI]
6 The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
Bruna de Souza Faustino,Alberto dos Reis Costa Junior,L.N.M. Bortolon,L.B.P.C. de Sá,D.R.T.W. Rocha,Alberto Krayyem Arbex
Open Journal of Endocrine and Metabolic Diseases. 2016; 06(01): 87
[Pubmed]  [Google Scholar] [DOI]
7 Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action
Prachi Gupta,Manju Bala,Sanjeev Gupta,Anita Dua,Rajesh Dabur,Elisha Injeti,Ashwani Mittal
Pharmacological Research. 2016; 113: 636
[Pubmed]  [Google Scholar] [DOI]
8 Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
Ranjeet Prasad Dash,R. Jayachandra Babu,Nuggehally R. Srinivas
Xenobiotica. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using11C-MDG
Keisuke Mitsuoka,Yuka Hayashizaki,Yoshihiro Murakami,Toshiyuki Takasu,Masanori Yokono,Nobuhiro Umeda,Shoji Takakura,Akihiro Noda,Sosuke Miyoshi
Pharmacology Research & Perspectives. 2016; 4(4): e00244
[Pubmed]  [Google Scholar] [DOI]

 

Read this article